Clinical trials - Cancer Research SA

Filter By

Luca-MERIT-1 BNT-116-01

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Lung Cancer – 2nd line and beyond: Luca-MERIT-1 BNT-116-01

LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
Read more: Lung Cancer – 2nd line and beyond: Luca-MERIT-1 BNT-116-01
AHEAD-MERIT BNT-113-01

Phase 2

Open and recruiting

Head and Neck SCC 1st line: HPV16+ PD-L1(+)

An open-label Phase II/III randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
Read more: Head and Neck SCC 1st line: HPV16+ PD-L1(+)
IMC-P115C-1-005

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours PRAME (+): IMC-P115C-1-005

A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01 Positive Participants with Advanced PRAME Positive Cancers
Read more: Advanced Solid Tumours PRAME (+): IMC-P115C-1-005
DT-7012-CLI-002

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours: DT-7012-CLI-002

A Phase 1/2a, multicentre, open-label clinical trial of DT-7012 in participants with advanced solid tumours
Read more: Advanced Solid Tumours: DT-7012-CLI-002
BG-75202-101

Phase 1, Phase 1a

Open and recruiting

Breast, Prostate KAT6A/B inhibitor: BG-75202-101

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors
Read more: Breast, Prostate KAT6A/B inhibitor: BG-75202-101
MTAP AMG193 20230153

Phase 2

Open and recruiting

Lung cancer: MTAP deleted with AMG193

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with Methylthioadenosine Phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Read more: Lung cancer: MTAP deleted with AMG193
Spago 177Lu-SN201 Tumorad

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Theranostics: Advanced solid tumours with Lutetium Tumorad

A Phase I/IIa, dose escalation and dose expansion, first-in-human, open-label, multicenter, single-arm study evaluating the safety, tolerability, dosimetry, and early efficacy of [177Lu]Lu- SN201 in participants with progressive or treatment-refractory locally advanced unresectable, metastatic or recurrent solid tumors – SPAGO TumoRAD
Read more: Theranostics: Advanced solid tumours with Lutetium Tumorad
GS-US-600-6165 / EVOKE-SCLC-04

Phase 3

Open and recruiting

Small cell lung cancer: Second line Sacituzumab versus SoC

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer – GS-US-600-6165 / EVOKE-SCLC-04
Read more: Small cell lung cancer: Second line Sacituzumab versus SoC
INCA036873

Phase 1, Phase 1a, Phase 1b

Open and recruiting

Advanced Solid Tumours – INCA036873 –

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Read more: Advanced Solid Tumours – INCA036873 –